Mosaic NeuroSciences is a subsidiary of Prediction BioSciences (Lyon, France) with the mission of developing new therapeutic solutions to resolve and improve the quality of life of patients suffering from neurodegenerative disorders as Frontotemporal Dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS). The Company has established strategic partnerships with organizations and companies possessing complementary expertise and technologies to achieve its research activities and is always open to new collaborations opportunities.

FTD is a severe and fatal disease of the brain characterized by massive loss of cortical neurons. A deficiency in the secreted growth factor Progranulin (PGRN) was found to be causative for a specific subtype of FTD, the behavioral variant FTD (bvFTD). The Company has a wide-ranging R&D program particularly in GRN haploinsufficiency-induced FTD : • A drug discovery program aiming at validating therapeutic targets to overcome Progranulin-deficient FTD. • The development of an extracellular vesicles-based platform, brain cell specific, to deliver a therapeutic cargo to disease-modified brain cells. Such delivery device would be applicable for a wide range of neurological disorders.